ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0781

Comprehensive mass cytometry analyses of disease-related cells in adult-onset Still’s disease

Hiroto Yoshida1, Mayu Magi1, Hiroya Tamai2, Kotaro Matsumoto2, Keiko Yoshimoto2, Tetsuhiro Soeda1 and Yuko Kaneko2, 1Chugai Pharmaceutical Co., Ltd. Product Research Dept., Yokohama, Kanagawa, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan

Meeting: ACR Convergence 2025

Keywords: immunology, Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases (0777–0782)

Session Type: Abstract Session

Session Time: 2:00PM-2:15PM

Background/Purpose: Adult-onset Still’s Disease (AOSD) is a rare autoinflammatory disorder characterized by high fever, rash, and arthritis. Although overactivation of macrophages, an increase in specific neutrophils, disruption of Th17/Treg cell balance, and decreased NK cell function have been reported in the pathogenesis of AOSD, the detailed roles and interactions of these immune cells in various aspects of the disease pathogenesis remain unclear. This study aimed to identify disease-related cell populations through comprehensive immunophenotyping analysis by mass cytometry.

Methods: Mass cytometry of peripheral whole blood was performed using 50 samples from patients with AOSD (six untreated active and forty-four in clinically inactive disease [CID]) and 21 control samples from healthy subjects (HC). Whole blood was stained with Maxpar Direct Immune Profiling Assay from Standard BioTools which contains antibodies of 30 markers and measured by Helios. The data was analyzed in Cytobank from Beckman Coulter. Dimensionality reduction and clustering analysis was performed using tSNE-CUDA and FlowSOM.

Results: The proportions of B cells, NK cells, and gamma delta T cells were significantly decreased in the active AOSD group compared to the HC group. These changes in cell subset proportions were persistent even after achieving CID. For more detailed analysis, we used FlowSOM clustering to divide those cells into 400 clusters. In the active AOSD group, the proportions of 66 clusters were significantly higher compared with the HC group. Among the increased cell clusters, 21 clusters were not different between the CID and HC groups, including CD4 cells, CD8 cells, monocytes, neutrophils, and eosinophils. Based on the expression patterns, the monocytes were characterized as intermediate monocytes with upregulated CD11c and HLA-DR and downregulated CD38. The CD4 cells exhibited features of effector memory cells, characterized by upregulation of CXCR3, CCR4, CD28, CD38, and HLA-DR, along with downregulation of CD27 and CD127. Similarly, the CD8 cells were also classified as effector memory cells, showing upregulation of CXCR3, CD27, CD28, CD38, and HLA-DR, and downregulation of CD57 and CD127.

Conclusion: Comprehensive and detailed mass cytometry analysis of peripheral blood cells from patients with AOSD identified characteristic intermediate monocytes and effector memory T cells were increased in the active phase and normalized after achieving CID. Those cell subsets may play an important role in the pathogenesis of AOSD and can be a new therapeutic target.

Supporting image 1Dimensionality reduction by tSNE-CUDA in mass cytometry data of peripheral blood cells

Supporting image 2Cell subsets increased in untreated active AOSD and normalized upon CID

Supporting image 3Heatmap of marker expression in cell subsets normalized upon CID


Disclosures: H. Yoshida: Chugai Pharmaceutical Co., Ltd., 3; M. Magi: Chugai Pharmaceutical Co., Ltd., 3; H. Tamai: None; K. Matsumoto: None; K. Yoshimoto: None; T. Soeda: Chugai Pharmaceutical Co., Ltd., 3; Y. Kaneko: AbbVie, 2, 5, 6, Asahi Kasei, 2, 5, 6, Astellas Pharma, 6, AstraZeneca, 6, Ayumi, 5, 6, Boehringer-Ingelheim, 5, Bristol-Myers Squibb, 2, 6, Chugai Pharmaceutical, 5, 6, Daiichi Sankyo, 6, Eisai, 5, 6, Eli Lilly, 2, 6, Gilead Sciences, 2, 5, 6, Glaxo SmithKline, 6, Janssen, 6, Mitsubishi Tanabe Pharma, 5, 6, Novartis, 6, Pfizer, 2, 6, Sanofi, 6, Taisho Pharmaceutical, 2, 5, 6, UCB, 2, 5, 6.

To cite this abstract in AMA style:

Yoshida H, Magi M, Tamai H, Matsumoto K, Yoshimoto K, Soeda T, Kaneko Y. Comprehensive mass cytometry analyses of disease-related cells in adult-onset Still’s disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/comprehensive-mass-cytometry-analyses-of-disease-related-cells-in-adult-onset-stills-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comprehensive-mass-cytometry-analyses-of-disease-related-cells-in-adult-onset-stills-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology